SLC5A2 and Hypoglycemia: This included deprescribing four antihyperglycaemic medications in the sulfonylurea (32 vs. 28 at study entry and exit, respectively) class in four patients and switching them to medications with a lower risk of hypoglycaemia (two patients received GLP-1 agonists and two received SGLT2 inhibitors).